BackPoniard Pharmaceuticals Overview

Poniard Pharmaceuticals Net Income

Latest net income for PARD: $-16M, below the Healthcare sector average of $1.5T.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$3.77M
↑ 41.53% YoY

As of Sep 2011

Annual Net Income (TTM)

-$16.04M
↑ 57.84% YoY

Trailing 12 months ending Sep 2011

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Poniard Pharmaceuticals (PARD) FAQ

As of the most recent data (September 2011), PARD shows a net income of $-16M. That compares with $-38M in the prior-year period — up 57.8% year over year. That is below the Healthcare sector average of $1.5T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PARD's net income is now $-16M (was $-38M) — a 57.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Poniard Pharmaceuticals is outperforming or lagging.

The Healthcare sector average net income is about $1.5T. Poniard Pharmaceuticals is at $-16M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how PARD stacks up against individual peers as well.

Tracking PARD's net income over time shows whether Poniard Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-16M That compares with $-38M in the prior-year period — up 57.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Poniard Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-16M) with ownership activity and broader fundamentals.